Aranzazu Gonzalez-Del-Alba
Overview
Explore the profile of Aranzazu Gonzalez-Del-Alba including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
76
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pelaez I, Lazaro-Quintela M, Perez-Fentes D, Esteban-Gonzalez E, Gallardo E, Alvarez-Fernandez C, et al.
Clin Transl Oncol
. 2025 Feb;
PMID: 39961959
Prostate, bladder and kidney neoplasms are among the most prevalent genitourinary (GU) cancers worldwide. Significant therapeutic advancements in recent years have substantially improved patient outcomes. In response to this rapid...
2.
Vidal N, Climent M, Perez S, Mendez-Vidal M, Anguera G, Martinez Salas I, et al.
Clin Transl Oncol
. 2024 Oct;
PMID: 39369361
Introduction: The COVID-19 pandemic is a great burden worldwide, but its impact on patients with genitourinary cancer (GUC) is poorly characterized. This study aimed to characterize the clinical features and...
3.
Perez-Navarro E, Conteduca V, Funes J, Dominguez J, Martin-Serrano M, Cremaschi P, et al.
Cancers (Basel)
. 2024 Jul;
16(14).
PMID: 39061175
The prognosis for patients with metastatic castration-resistant prostate cancer (mCRPC) varies, being influenced by blood-related factors such as transcriptional profiling and immune cell ratios. We aimed to address the contribution...
4.
Font A, Mellado B, Climent M, Virizuela J, Oudard S, Puente J, et al.
Br J Cancer
. 2023 Dec;
130(3):434-441.
PMID: 38102226
Background: Preclinical and early clinical data suggest that the irreversible ErbB family blocker afatinib may be effective in urothelial cancers harbouring ERBB mutations. Methods: This open-label, phase II, single-arm trial...
5.
Romero-Laorden N, Lorente D, de Velasco G, Lozano R, Herrera B, Puente J, et al.
Eur Urol Oncol
. 2023 Oct;
7(3):447-455.
PMID: 37838555
Background: Radium-223 is an active therapy option for bone metastatic castration-resistant prostate cancer (mCRPC). The lack of adequate biomarkers for patient selection and response assessment are major drawbacks for its...
6.
Mendez-Vidal M, Lazaro Quintela M, Lainez-Milagro N, Perez-Valderrama B, Suarez Rodriguez C, Arranz Arija J, et al.
Clin Transl Oncol
. 2023 Aug;
25(9):2732-2748.
PMID: 37556095
Renal cancer is the seventh most common cancer in men and the tenth in women. The aim of this article is to review the diagnosis, treatment, and follow-up of renal...
7.
Gillessen S, Procopio G, Hayoz S, Kremer E, Schwitter M, Caffo O, et al.
J Clin Oncol
. 2023 Feb;
41(20):3608-3615.
PMID: 36753698
Purpose: To assess the efficacy and safety of darolutamide maintenance after successful taxane chemotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC). Patients And Methods: Swiss Group for Clinical Cancer...
8.
Fernandez-Perez M, Perez-Navarro E, Alonso-Gordoa T, Conteduca V, Font A, Vazquez-Estevez S, et al.
Prostate
. 2022 Dec;
83(4):376-384.
PMID: 36564933
Background: There is a considerable need to incorporate biomarkers of resistance to new antiandrogen agents in the management of castration-resistant prostate cancer (CRPC). Methods: We conducted a phase II trial...
9.
Torrente M, Blanco M, Franco F, Garitaonaindia Y, Calvo V, Collazo-Lorduy A, et al.
Front Cardiovasc Med
. 2022 Dec;
9:1062858.
PMID: 36531707
Background: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. However, despite their excellent therapeutic effect, these medications typically result in a broad spectrum of toxicity reactions. Immune-related cardiotoxicity is uncommon...
10.
Rodriguez Perez A, Felip Font E, Chicas-Sett R, Montero-Luis A, de Paz Arias L, Gonzalez-Del-Alba A, et al.
Clin Transl Oncol
. 2022 Dec;
25(4):882-896.
PMID: 36525231
Oligometastatic disease (OMD) defines a cancer status that is intermediate between localized and widely spread metastatic disease, and can be treated with curative intent. While diagnostic imaging tools have considerably...